Aclarion Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ACON Nasdaq 8731 http://aclarion.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aclarion Inc

Insiders who bought stock earlier this year lose -US$213k as Aclarion, Inc. (NASDAQ:ACON) drops to US$4.7m - Feb 5th, 2023 1:50 pm
Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor - Jan 31st, 2023 3:01 pm
Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor - Jan 17th, 2023 1:29 pm
Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event - Jan 17th, 2023 1:00 pm
Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor - Dec 22nd, 2022 3:36 pm
Aclarion’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD - Dec 21st, 2022 3:23 pm
Aclarion Adds to Growing Key Opinion Leader Program with Juan Uribe M.D. as a Surgeon Advisor - Dec 19th, 2022 1:33 pm
Aclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator Biomarker - Dec 1st, 2022 2:41 pm
Aclarion Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags - Nov 16th, 2022 10:12 am
Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV - Oct 25th, 2022 11:00 am
Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor - Oct 24th, 2022 11:00 am
Aclarion To Present at The LD Micro Main Event XV - Oct 12th, 2022 11:00 am
Aclarion Announces Participation at the NASS 37th Annual Meeting - Oct 10th, 2022 11:05 am
John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor - Oct 3rd, 2022 11:03 am
Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain - Sep 19th, 2022 11:03 am
Aclarion, Inc. to Present at Investor Summit Group's Q3 Virtual Conference - Aug 4th, 2022 11:00 am
Quite a few insiders invested in Aclarion, Inc. (NASDAQ:ACON) last year which is positive news for shareholders - Jul 22nd, 2022 1:01 pm
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan - Jul 20th, 2022 11:00 am
Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain - Jun 22nd, 2022 11:00 am
Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering - Apr 27th, 2022 1:15 am